Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
<p>Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus concomitant and adjuvant temozolomide (TMZ), provides less than 15-month survival benefit. Efforts by conve...
Main Authors: | Johanssen, T, McVeigh, L, Erridge, S, Higgins, G, Straehla, J, Frame, M, Aittokallio, T, Carragher, NO, Ebner, D |
---|---|
Format: | Journal article |
Published: |
Frontiers Media
2023
|
Similar Items
-
A chemogenomic HTS for combinatorial drug discovery in glioblastoma
by: Johanssen, T, et al.
Published: (2022) -
Where are all the surgeons in clinical academia?
by: McVeigh, J, et al.
Published: (2022) -
Recent advances in the therapeutic strategies of glioblastoma multiforme
by: Aldoghachi, Asraa Faris, et al.
Published: (2022) -
Accelerating glioblastoma therapeutics via venture philanthropy
by: Siah, Kien Wei, et al.
Published: (2022) -
The violinist in London's concert life, 1750-1784 : Felice Giardini and his contemporaries
by: McVeigh, S
Published: (1979)